BR112013033192A2 - fenilbutirato na forma retal para o tratamento de uma doença neuronal motora, um distúrbio do ciclo de úreia ou câncer - Google Patents

fenilbutirato na forma retal para o tratamento de uma doença neuronal motora, um distúrbio do ciclo de úreia ou câncer

Info

Publication number
BR112013033192A2
BR112013033192A2 BR112013033192A BR112013033192A BR112013033192A2 BR 112013033192 A2 BR112013033192 A2 BR 112013033192A2 BR 112013033192 A BR112013033192 A BR 112013033192A BR 112013033192 A BR112013033192 A BR 112013033192A BR 112013033192 A2 BR112013033192 A2 BR 112013033192A2
Authority
BR
Brazil
Prior art keywords
phenylbutyrate
rectal
cancer
treatment
urea cycle
Prior art date
Application number
BR112013033192A
Other languages
English (en)
Inventor
Marini Frédéric
Original Assignee
Gmp Orphan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmp Orphan filed Critical Gmp Orphan
Publication of BR112013033192A2 publication Critical patent/BR112013033192A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013033192A 2011-06-22 2012-06-22 fenilbutirato na forma retal para o tratamento de uma doença neuronal motora, um distúrbio do ciclo de úreia ou câncer BR112013033192A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161499805P 2011-06-22 2011-06-22
PCT/EP2012/062152 WO2012175714A1 (en) 2011-06-22 2012-06-22 Phenylbutyrate in rectal form for the treatment of a motor neuron disease or a metabolic disease

Publications (1)

Publication Number Publication Date
BR112013033192A2 true BR112013033192A2 (pt) 2017-08-08

Family

ID=46384377

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033192A BR112013033192A2 (pt) 2011-06-22 2012-06-22 fenilbutirato na forma retal para o tratamento de uma doença neuronal motora, um distúrbio do ciclo de úreia ou câncer

Country Status (8)

Country Link
US (1) US20140187638A1 (pt)
EP (1) EP2723317A1 (pt)
JP (1) JP2014517057A (pt)
AU (1) AU2012273976A1 (pt)
BR (1) BR112013033192A2 (pt)
CA (1) CA2840131A1 (pt)
RU (1) RU2014100048A (pt)
WO (1) WO2012175714A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3005434A1 (en) 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
US20170266115A1 (en) * 2016-03-15 2017-09-21 Acer Therapeutics Inc. Palatable compositions including sodium phenylbutyrate and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400184D0 (sv) 2004-01-30 2004-01-30 Fyrkloevern Scandinavia Ab New therapeutical use
US20060045912A1 (en) * 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use

Also Published As

Publication number Publication date
RU2014100048A (ru) 2015-07-27
CA2840131A1 (en) 2012-12-27
WO2012175714A1 (en) 2012-12-27
AU2012273976A1 (en) 2014-01-16
US20140187638A1 (en) 2014-07-03
EP2723317A1 (en) 2014-04-30
JP2014517057A (ja) 2014-07-17

Similar Documents

Publication Publication Date Title
BR112013029507A2 (pt) método para tratar uma doença ou um distúrbio
BR112014032105A2 (pt) método para o tratamento de câncer
BR112014007603A2 (pt) métodos de tratamento do câncer
BR112015001596A2 (pt) composição para o tratamento de hiperlipidemia que compreende oxintomodulina.
CO6890100A2 (es) Tratamientos de combinación para hepatitis c
BR112014016732A2 (pt) processos para tratar lama vermelha
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
DK2707030T3 (da) Cancerbehandlinger
BR112013021783A2 (pt) sutiã para tratamento com radiação
BR112014002200A2 (pt) tratamento de câncer de mama
BR112014031806A2 (pt) método para tratamento de câncer positivo para gd2
HK1203417A1 (en) New therapeutic approaches for treating parkinsons disease
BR112014000033A2 (pt) compostos para o tratamento de dependência química
BR112014006419A2 (pt) métodos para tratar um paciente com câncer, kit e artigo
BR112014012880A2 (pt) tratamento imunogênico do câncer
BR112013030381A2 (pt) reagentes e métodos para tratar doença dental
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BR112013031712A2 (pt) composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0922884A2 (pt) compostos para tratamento de câncer
BR112012000098A2 (pt) Processo para identificação de compostos para tratar câncer
BR112013025340A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado com pi3k num indivíduo necessitado, método para tratar doença mediada por hdac e método para tratar tanto doenças mediadas por pi3k como por hdac
BR112015002526A2 (pt) processo para a fabricação de isavuconazol ou ravuconazol
BR112012008959A2 (pt) tratamento de terapia de combinação para infecções virais
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]